Phillip G. Claringbold

927 total citations
12 papers, 695 citations indexed

About

Phillip G. Claringbold is a scholar working on Epidemiology, Oncology and Neurology. According to data from OpenAlex, Phillip G. Claringbold has authored 12 papers receiving a total of 695 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Epidemiology, 9 papers in Oncology and 8 papers in Neurology. Recurrent topics in Phillip G. Claringbold's work include Neuroendocrine Tumor Research Advances (10 papers), Neuroblastoma Research and Treatments (8 papers) and Lung Cancer Research Studies (8 papers). Phillip G. Claringbold is often cited by papers focused on Neuroendocrine Tumor Research Advances (10 papers), Neuroblastoma Research and Treatments (8 papers) and Lung Cancer Research Studies (8 papers). Phillip G. Claringbold collaborates with scholars based in Australia and United States. Phillip G. Claringbold's co-authors include J. Harvey Turner, R. Arlen Price, Murali Kesavan, J Bouček, David M. Hurley, Michael F. Leahy, P. Gerry Fegan, David Henley, Gregory S Y Ong and Wei‐Sen Lam and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and European Journal of Endocrinology.

In The Last Decade

Phillip G. Claringbold

12 papers receiving 680 citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Phillip G. Claringbold 536 528 427 200 80 12 695
Maribel Lopera Sierra 452 0.8× 514 1.0× 353 0.8× 159 0.8× 44 0.6× 24 640
Jan-Paul Esser 485 0.9× 606 1.1× 422 1.0× 242 1.2× 55 0.7× 6 751
Marianne E. Pavel 470 0.9× 564 1.1× 369 0.9× 256 1.3× 98 1.2× 11 748
Beth Chasen 343 0.6× 369 0.7× 261 0.6× 122 0.6× 63 0.8× 19 557
M. Caracciolo 274 0.5× 239 0.5× 131 0.3× 106 0.5× 27 0.3× 5 572
Janet Lasher 191 0.4× 220 0.4× 138 0.3× 125 0.6× 31 0.4× 8 343
C. Bouriel 198 0.4× 154 0.3× 131 0.3× 216 1.1× 52 0.7× 8 428
Eric von Benzon 191 0.4× 160 0.3× 93 0.2× 205 1.0× 106 1.3× 15 414
Torjan Haslerud 445 0.8× 471 0.9× 353 0.8× 183 0.9× 79 1.0× 24 668
Swantje Engelbrecht 245 0.5× 289 0.5× 216 0.5× 107 0.5× 34 0.4× 7 383

Countries citing papers authored by Phillip G. Claringbold

Since Specialization
Citations

This map shows the geographic impact of Phillip G. Claringbold's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Phillip G. Claringbold with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Phillip G. Claringbold more than expected).

Fields of papers citing papers by Phillip G. Claringbold

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Phillip G. Claringbold. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Phillip G. Claringbold. The network helps show where Phillip G. Claringbold may publish in the future.

Co-authorship network of co-authors of Phillip G. Claringbold

This figure shows the co-authorship network connecting the top 25 collaborators of Phillip G. Claringbold. A scholar is included among the top collaborators of Phillip G. Claringbold based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Phillip G. Claringbold. Phillip G. Claringbold is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
2.
Kesavan, Murali, et al.. (2021). Long-term hematologic toxicity of 177Lu-octreotate-capecitabine-temozolomide therapy of GEPNET. Endocrine Related Cancer. 28(7). 521–527. 19 indexed citations
3.
4.
Claringbold, Phillip G. & J. Harvey Turner. (2015). NeuroEndocrine Tumor Therapy with Lutetium-177-octreotate and Everolimus (NETTLE): A Phase I Study. Cancer Biotherapy and Radiopharmaceuticals. 30(6). 261–269. 74 indexed citations
5.
Claringbold, Phillip G. & J. Harvey Turner. (2015). Pancreatic Neuroendocrine Tumor Control: Durable Objective Response to Combination <sup>177</sup>Lu-Octreotate-Capecitabine-Temozolomide Radiopeptide Chemotherapy. Neuroendocrinology. 103(5). 432–439. 79 indexed citations
6.
Kesavan, Murali, Phillip G. Claringbold, & J. Harvey Turner. (2014). Hematological Toxicity of Combined <sup>177</sup>Lu-Octreotate Radiopeptide Chemotherapy of Gastroenteropancreatic Neuroendocrine Tumors in Long-Term Follow-Up. Neuroendocrinology. 99(2). 108–117. 53 indexed citations
7.
Claringbold, Phillip G., R. Arlen Price, & J. Harvey Turner. (2012). Phase I-II Study of Radiopeptide 177 Lu-Octreotate in Combination with Capecitabine and Temozolomide in Advanced Low-Grade Neuroendocrine Tumors. Cancer Biotherapy and Radiopharmaceuticals. 27(9). 561–569. 131 indexed citations
8.
Claringbold, Phillip G., et al.. (2010). Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging. 38(2). 302–311. 165 indexed citations
9.
Ong, Gregory S Y, et al.. (2010). Therapies for the medical management of persistent hypoglycaemia in two cases of inoperable malignant insulinoma. European Journal of Endocrinology. 162(5). 1001–1008. 41 indexed citations
10.
Claringbold, Phillip G., et al.. (2009). Lutetium-177 octreotate radiopeptide therapy of endocrine cancer: Tumor and critical organ dosimetry. 50. 499–499. 1 indexed citations
11.
12.
Claringbold, Phillip G., et al.. (1991). A phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose samarium-153 ethylenediaminetetramethylene phosphonate. European Journal of Cancer and Clinical Oncology. 27(9). 1084–1086. 79 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Maribel Lopera Sierra Breakdown of academic impact, for papers by Jan-Paul Esser Breakdown of academic impact, for papers by Marianne E. Pavel Breakdown of academic impact, for papers by Beth Chasen Breakdown of academic impact, for papers by M. Caracciolo Breakdown of academic impact, for papers by Janet Lasher Breakdown of academic impact, for papers by C. Bouriel Breakdown of academic impact, for papers by Eric von Benzon Breakdown of academic impact, for papers by Torjan Haslerud Breakdown of academic impact, for papers by Swantje Engelbrecht
Rankless by CCL
2026